Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma-Reference-Cited by-同舟云学术

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

Published:2021-09-29 Issue:10 Volume:125 Page:1365-1376
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Aliagas Elisabet,Alay Ania,Martínez-Iniesta Maria,Hernández-Madrigal Miguel,Cordero David,Gausachs Mireia,Pros Eva,Saigí Maria^ORCID,Busacca Sara,Sharkley Annabel J.,Dawson Alan,Palmero Ramón,Ruffinelli José C.,Padrones Susana,Aso Samantha,Escobar Ignacio,Ramos Ricard,Llatjós Roger,Vidal August^ORCID,Dorca Eduard,Varela Mar,Sánchez-Céspedes Montse,Fennell Dean,Muñoz-Pinedo Cristina,Villanueva Alberto,Solé Xavi^ORCID,Nadal Ernest^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-021-01547-y.pdf

Reference40 articles.

1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716–24, 24A–24C.

2. Chen T, Sun XM, Wu L. High time for complete ban on asbestos use in developing countries. JAMA Oncol. 2019;5:779–80.

3. Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci USA. 2019;116:9008–13.

4. Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36:2863–71.

5. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022–5.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Approaches to Treatment of Pleural Mesothelioma: A Review;JCO Precision Oncology;2023-09

2. Immunomodulatory effects of CDK4/6 inhibitors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07

3. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4 /6 inhibition;Molecular Oncology;2022-12-19

4. CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells;Cancers;2022-11-30

5. Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells;Frontiers in Pharmacology;2022-06-23